Desk Rejection at Medical Journals: What the 2026 Data Reveals for Authors

Desk rejection is the part of academic publishing that authors discuss quietly and track badly. It happens before peer review, leaves no public record, and arrives without much explanation. For many medical researchers, it is the most common form of rejection they will ever experience at a selective journal, yet most have only a rough sense of why it happens or how much of it is within their control. A study published in 2026 in the International Journal of Public Health offers one of the most direct examinations of the question in years, and its finding is uncomfortable: editors at the same journal, reviewing the same papers, agreed on desk rejection decisions for only 43 percent of manuscripts at the first screening stage. The kappa statistics describing their agreement hovered between 0.52 and 0.57. That range describes moderate agreement, not strong consensus. The implications for how authors should think about pre-screening rejection are significant.

None of this means desk rejection is random, or that preparation does not matter. The study also showed that overall rejection rates increased at the second stage as editors refined their assessments, which means the papers most clearly outside scope or below threshold were consistently removed. The disagreement came at the margins, for papers that editors experienced differently depending on their own areas of expertise, their sense of journal fit, and the framing they encountered first. That marginal group is exactly where good submission strategy operates. Understanding both the systematic part of desk rejection and its genuinely subjective element changes how you approach a submission.

How Pre-Screening Actually Works at Medical Journals

Most medical journals do not describe their desk rejection process in detail on their author guidelines pages. What authors encounter is a statement that manuscripts may be returned without review if they do not meet scope requirements, and perhaps a note that the editorial office conducts an initial quality check. In practice, the process varies considerably across journal types and publishers. At some journals, a managing editor or editorial coordinator does a first pass for completeness and article type before the manuscript reaches a handling editor. At others, handling editors see the submission immediately and make an independent judgment. At high-volume journals, this initial read may last only a few minutes.

The two-stage structure used at the International Journal of Public Health, in which two or three editors independently screen each paper before reaching a joint decision, is more rigorous than most journals employ. The fact that even this careful process produced agreement in fewer than half of Stage 1 assessments gives authors a realistic picture of the judgment involved. The editors in that study were not careless. Their divergence reflected genuine differences in how expert readers interpret scope boundaries and assess novelty under time pressure. Some papers land on an editor who finds them compelling. Others land on someone who reads the same abstract and sees a mismatch. That variability is not fully preventable, but it is partially manageable.

Understanding this has a practical implication that authors rarely discuss openly: the journal you target matters partly because of who its editors are, not just what the journal publishes. An editor whose primary expertise aligns with your intervention area or methodological approach will evaluate your manuscript differently from one who is primarily a generalist handling a busy queue. Reading recent editorial board listings, looking at who has edited papers close to your own, and checking whether the journal has handled work at the intersection of your topic with other disciplines are all ways of making the editorial lottery marginally more favorable.

Desk Rejection Rates by Journal Tier in 2026

The numbers vary dramatically across the landscape of medical publishing, and any specific figure depends heavily on the time period, submission volume, and how a journal defines its own threshold. That said, the general ranges are now well-documented. PLOS ONE, which uses a soundness-only peer review model and accepts papers from across biomedical research, desk-rejects roughly 15 percent of submissions. Journals in the first quartile by impact factor typically send between 50 and 60 percent of manuscripts back without review. At the most selective end, NEJM operates closer to 90 to 95 percent desk rejection, often within 48 hours of submission, based primarily on the structured abstract and key points summary that the journal requires. JAMA sits in a similar range, around 80 percent.

One finding that has circulated in editorial discussions for some years, but is worth naming directly, is that elite journals desk-reject a large share of papers that eventually go on to become highly cited after publication elsewhere. Analysis of manuscripts at three leading journals found that the majority of papers later recognized as among the most influential in their field had been desk rejected at those same journals before finding a home elsewhere. This does not mean editors are wrong to desk reject, because they are working under different constraints than a researcher assessing historical impact years later. It does mean authors should treat desk rejection from a selective journal as a signal about fit with that journal at that moment, not as a verdict on the scientific contribution.

These rates carry a specific implication for how authors should build submission strategies. Targeting a journal where 90 percent of manuscripts never reach a reviewer means you are engaging in an inherently low-probability step. That step may still be worth taking for the right paper, but it should not be the only step in your plan. Working out your second and third submission targets before you submit to the most selective journal is not defeatism. It is realistic resource management for research teams whose time is limited.

The Most Common Reasons Manuscripts Are Desk Rejected

Scope mismatch is the single most cited reason across studies of desk rejection decisions. This means the paper covers a topic the journal does not prioritize, uses a study design the journal rarely handles, or addresses a clinical question outside the reader population the editors are writing for. Scope mismatch is also the category authors most frequently dispute, because they read the journal's aims and scope page and found their topic mentioned. The problem is that scope pages describe a territory, not a priority list. A general cardiology journal that says it publishes research on cardiac arrhythmias is not telling you it welcomes a small retrospective study of AF burden in a single regional center. Scope language is broad by design. Editorial priorities are narrower and shift over time.

Novelty and impact thresholds account for another large share of desk rejections at selective journals. This is the category where the subjective element from the 2026 IJPH study is most visible. Two editors can read the same paper and reach different conclusions about whether the finding advances the field enough to warrant peer review time. One may see an important confirmatory result in an understudied population. The other may see an incremental addition to a well-established literature. The clinical relevance of the outcome, the size and quality of the dataset, and the clarity with which the authors articulate why the finding matters all influence this read, and none of those factors is entirely within editorial control.

Technical and formatting failures round out the main causes. These are the most preventable category. A manuscript that exceeds the word limit, uses the wrong reference style, omits mandatory reporting checklists, does not include required ethics statements, or is formatted for a different journal's template signals to an editor that the submission was not prepared carefully for this venue. That impression is difficult to separate from the first read of the science. Some journals have explicit policies allowing immediate return without review for technical non-compliance. Others leave it to editorial discretion. Either way, the failure creates administrative friction and gives an editor who is already uncertain a concrete reason to send the paper back.

What NEJM-Style Journals Screen In the First Minutes

The New England Journal of Medicine requires a structured abstract of 250 words or fewer and a brief Key Points summary with three bullet items at submission. These two elements carry an outsized share of the weight in the initial editorial read. At a journal receiving several hundred original research submissions per week, the abstract and key points are often the primary material a senior editor uses to decide within the first few minutes whether the paper warrants more attention. If those elements do not communicate, on their own, why the study matters, why the population is well-chosen, and what the finding adds to existing clinical knowledge, the manuscript faces a very high risk of desk rejection before the introduction is read.

This has a practical consequence that authors at every stage of their careers sometimes miss. Writing the abstract and key points last, as a summary of work already completed, is a natural sequence. But at journals like NEJM, JAMA, and The Lancet, those elements function as a pitch document, not a summary. They should be written with the same care as a grant abstract, with an explicit statement of what is not already known and why this study answers that gap in a way others have not. Reviewers who eventually see the manuscript will read those elements too, but editors who never reach the reviewers will decide entirely on the basis of them.

The same principle applies to cover letters at journals that give them serious editorial weight. BMJ and The Lancet have both stated that the cover letter influences initial editorial assessment. A cover letter that describes the research question accurately, names two or three papers the study advances beyond, and explains why the journal's readership in particular would benefit from the finding is doing substantive work. A cover letter that reads as a generic summary of the abstract is doing none.

The Formatting and Compliance Layer Authors Underestimate

Editors at busy journals have developed a quick-scan vocabulary for detecting submissions that were prepared for a different journal and rerouted without adequate adaptation. The signals include reference styles that do not match the target journal, figure legends structured for another publisher's format, abstract headers that align with a previous journal's template, supplementary files named in a convention foreign to the submission system, and mandatory sections (acknowledgments, author contributions, conflicts of interest) that are present but incomplete or mislocated. None of these mistakes is intellectually damaging. Together they create an impression of a submission that was not prepared carefully for this venue, and that impression is hard to separate from the first editorial read of the science.

Reporting guideline compliance is a particularly common gap. Journals in the BMJ family, Annals of Internal Medicine, JAMA Network Open, and many Springer Nature titles now require that authors upload the completed CONSORT, PRISMA, STROBE, or equivalent checklist at submission for clinical trials, systematic reviews, and observational studies respectively. At some journals, the submission system will not allow completion without this file. At others, the absence is caught at desk review. Either way, submitting without the completed checklist signals that the paper was not written with those standards in mind, which is itself informative to an editor assessing whether the methods will hold up under peer review.

Trial registration is a related compliance point that generates avoidable desk rejections. The ICMJE standard requires that clinical trials be registered in a public registry before first patient enrollment, and that the registration number appear in the abstract. Several journals have moved from recommending this to requiring it for all interventional studies, and some have extended the requirement to prospective observational work. Authors who registered their trial but did not include the registration number in the correct location, or who did not register at all because the study was not originally planned as a trial, encounter friction here that could have been avoided at the design stage.

A Pre-Submission Audit That Reduces Avoidable Desk Rejection

The pattern of desk rejection mistakes is consistent enough that a structured pre-submission review catches most of them before they become editorial problems. The following approach applies to any medical journal submission and takes roughly an hour for a prepared team.

Start with the journal's most recent aims and scope page, not a cached version from months ago. Note the specific article types the journal prioritizes, the populations or disease areas it covers, and any explicit exclusions. Then check two or three papers the journal published in the past six months that are closest to your own work. If you cannot identify two or three published papers with substantial methodological or topical overlap, that is a meaningful signal about fit. It does not mean the journal is the wrong choice, but it means you should be prepared to articulate explicitly in your cover letter why this journal is the right venue.

This kind of audit is most useful when done by someone other than the corresponding author. When you have been working on a manuscript for months, you stop seeing its gaps. A co-author who reads the paper as a fresh submission, checking compliance rather than content, will catch things the primary writer misses. If that is not practical, at minimum read the abstract and cover letter out loud after a 24-hour break. The framing problems that make desk rejection more likely are usually audible in the rhythm of the sentences before they are visible in the logic.

When Desk Rejection Is Useful Information

Most desk rejection letters say very little. A short note from an editor explaining that the paper does not fit the journal's current focus, without further specifics, is not a performance review of the science. It is a routing decision, often made quickly, based on limited information. The reflex to treat it as a judgment of quality is understandable but usually inaccurate. The right response is to retarget, not to rewrite for problems that were not identified.

That said, some desk rejections do carry information. If the same paper is desk rejected rapidly at multiple journals across a similar tier, and the authors are targeting journals where the paper genuinely seems to fit by scope and design, that pattern is worth attending to. It may indicate that the abstract is not framing the contribution clearly, that the study population is too narrow for the generalist readership being targeted, or that the clinical relevance section is underselling the finding. A careful read of the abstract from the perspective of someone who has never seen the project, and honest comparison with recently published papers at those journals, usually reveals what the framing is missing.

Occasionally a desk rejection arrives with a note from the editor that goes further than the standard form language. An editor who writes that the paper's sample size is too small for the primary outcome to be interpretable, or that the study design does not support the causal inference claimed in the discussion, is offering real feedback that should be taken seriously. Those cases are rare, but when they occur they are more informative than most peer reviews, because the editor is telling you something that would have been a barrier to acceptance even if the paper had reached review. Revising the manuscript to address that concern before the next submission is time well spent.

Building a Tiered Submission Strategy That Accounts for Desk Rejection

Most productive research teams, even when they do not name it as such, operate on a tiered submission model. They have a first-choice journal, a second-choice journal, and a third-choice journal for each major project, and they have enough familiarity with each journal's requirements that retargeting a rejected manuscript takes hours rather than days. Authors who do not think in tiers tend to submit to one journal, wait several months for a review outcome, and then start the targeting process again from scratch when it does not work. The cumulative time cost is significant.

When desk rejection rates are factored into the strategy explicitly, the tier structure changes somewhat. If your first-choice journal has a 90 percent desk rejection rate, you should not expect it to be a realistic primary path for most manuscripts. For most clinical research teams, the right first-choice journal is one where the paper is genuinely competitive for peer review, not one where the work might eventually clear a very high bar if conditions align. The very selective journals belong on the list, but they probably belong at the top as a real possibility rather than as the expected outcome.

The 2026 data on editorial agreement variability reinforces this framing. If two expert editors at the same journal disagree on which papers deserve review more than half the time, the difference between a desk rejection and a peer review assignment is, for a meaningful share of manuscripts, a matter of which editor happened to see the paper first. That variability argues for building a submission history rather than concentrating on any single journal for any single paper. A manuscript that is desk rejected today at a journal whose editorial team turns over, or where a new handling editor with a different topical background joins the board, may be appropriate for resubmission to that same journal a year later with a fresh abstract.

Further Reading